cGMP Signaling in Cardiovascular Diseases: Linking Genotype and Phenotype

J Cardiovasc Pharmacol. 2020 Jun;75(6):516-525. doi: 10.1097/FJC.0000000000000744.

Abstract

Cyclic guanosine 3',5'-monophosphate (cGMP) is the key second messenger molecule in nitric oxide signaling. Its rapid generation and fate, but also its role in mediating acute cellular functions has been extensively studied. In the past years, genetic studies suggested an important role for cGMP in affecting the risk of chronic cardiovascular diseases, for example, coronary artery disease and myocardial infarction. Here, we review the role of cGMP in atherosclerosis and other cardiovascular diseases and discuss recent genetic findings and identified mechanisms. Finally, we highlight open questions and promising research topics.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Cardiovascular Agents / therapeutic use
  • Cardiovascular Diseases / drug therapy
  • Cardiovascular Diseases / genetics*
  • Cardiovascular Diseases / metabolism*
  • Cardiovascular Diseases / physiopathology
  • Cardiovascular System / drug effects
  • Cardiovascular System / metabolism*
  • Cardiovascular System / physiopathology
  • Cyclic GMP / metabolism*
  • Genetic Variation*
  • Humans
  • Nitric Oxide / metabolism*
  • Phenotype
  • Second Messenger Systems / drug effects
  • Second Messenger Systems / genetics*

Substances

  • Cardiovascular Agents
  • Nitric Oxide
  • Cyclic GMP